USFDA Inspects Telangana Plant, Issues VAI Classification
Granules India Limited announced a regulatory update for its subsidiary, Granules Life Sciences. The U.S. Food and Drug Administration (USFDA) inspected its Telangana manufacturing plant from December 15-19, 2025, classifying it as Voluntary Action Indicated (VAI). The inspection report is issued, and the probe is closed with no regulatory action recommended. While this avoids immediate enforcement, the VAI status means compliance issues were identified, which the company is expected to fix voluntarily. This contrasts with a 'No Action Indicated' (NAI) status its U.S. subsidiary, Granules Consumer Health LLC, received in March for its Virginia packaging facility.
Stock Surges Despite Regulatory Findings, Analysts Remain Positive
Even with mixed regulatory news, Granules India's stock has shown strong performance, rising about 27.31% in the past year. Shares have traded between ₹412.05 and ₹640.00, currently trading near ₹624.35 as of late March 2026. The company has a market capitalization of approximately ₹15,391.91 crore. Granules India's trailing twelve-month Price-to-Earnings (P/E) ratio is around 27-28x. This valuation is higher than peers like Dr. Reddy's Laboratories (18.3x P/E) and Aurobindo Pharma (21.5x P/E), but lower than API specialists like Divi's Laboratories (63.7x P/E) and Laurus Labs (63.6x P/E). The Nifty Pharma Index trades at a P/E of 33.3x. Analysts remain positive, with a consensus 'Buy' recommendation and an average price target around ₹650-₹660, indicating potential upside.
History of Past USFDA Issues Raises Concerns
While Granules India points to positive outcomes like 'no regulatory action recommended,' the VAI classification itself signals identified compliance issues. This is concerning given the company's history. In August 2024, the USFDA issued a warning letter to Granules India's Gagillapur facility after an inspection noted six major violations. These included unclean equipment, unresolved production problems, repeat offenses, poor quality control records, and inadequate facility maintenance, even observing bird droppings near air units. Although a VAI status is less severe than an 'Official Action Indicated' (OAI), it confirms that objectionable conditions were found. For Granules India, which relies on regulated markets like the U.S. and faces industry scrutiny and price pressure, such findings underscore the need for constant, strict compliance. These issues could impact future product approvals or operational flexibility.
Company Strategy and Sector Growth Outlook
The Indian pharmaceutical sector is expected to grow 7-9% in FY2026, driven by domestic demand and strong European exports. The U.S. market, however, remains challenging due to price pressures and regulatory hurdles. Granules India is focusing on expanding its finished dosage formulations segment, particularly in North America, which made up 79% of its revenue in Q4 FY25. This strategy allows the company to benefit from sector growth. Management is confident in its ongoing initiatives, product improvements, and expansion of its non-legacy molecule portfolio. Successfully navigating changing regulatory demands across its facilities will be key for the company to maintain its growth and investor trust.